We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Genzyme Hit With 16-Observation 483 Over Lapses in Quality Controls
Genzyme Hit With 16-Observation 483 Over Lapses in Quality Controls
Genzyme received a 16-observation Form 483 from the FDA for not conducting risk assessments and other quality lapses at a facility where bulk drug substances are made.